Trial Profile

A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Busulfan (Primary) ; Busulfan (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Mesna (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary)
Indications Graft-versus-host disease
Focus Therapeutic Use
Acronyms OPTIMIZE

29 May 2025 Planned number of patients changed from 190 to 313.
13 Feb 2025 New trial record
10 Dec 2024 Study design presented at the 66th American Society of Hematology Annual Meeting and Exposition.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com